Intersect ENT Inc (NASDAQ:XENT) Expected to Announce Quarterly Sales of $24.23 Million

Share on StockTwits

Equities research analysts forecast that Intersect ENT Inc (NASDAQ:XENT) will post $24.23 million in sales for the current fiscal quarter, Zacks Investment Research reports. Five analysts have provided estimates for Intersect ENT’s earnings. The highest sales estimate is $26.01 million and the lowest is $23.23 million. Intersect ENT posted sales of $24.67 million in the same quarter last year, which would indicate a negative year-over-year growth rate of 1.8%. The company is scheduled to issue its next quarterly earnings results on Monday, November 4th.

On average, analysts expect that Intersect ENT will report full-year sales of $108.61 million for the current year, with estimates ranging from $108.10 million to $109.32 million. For the next year, analysts expect that the company will post sales of $122.07 million, with estimates ranging from $114.76 million to $133.05 million. Zacks Investment Research’s sales calculations are an average based on a survey of analysts that follow Intersect ENT.

Intersect ENT (NASDAQ:XENT) last announced its quarterly earnings data on Thursday, August 1st. The medical equipment provider reported ($0.36) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.34) by ($0.02). Intersect ENT had a negative net margin of 31.43% and a negative return on equity of 29.16%. The firm had revenue of $26.66 million during the quarter, compared to analysts’ expectations of $27.13 million. During the same period in the prior year, the company posted ($0.14) EPS. The company’s revenue for the quarter was up 1.4% compared to the same quarter last year.

A number of equities research analysts recently issued reports on XENT shares. Berenberg Bank lowered shares of Intersect ENT from a “buy” rating to a “hold” rating and dropped their price objective for the company from $35.00 to $27.00 in a report on Friday, June 21st. Zacks Investment Research lowered shares of Intersect ENT from a “hold” rating to a “strong sell” rating in a report on Friday, May 3rd. Leerink Swann lowered shares of Intersect ENT from an “outperform” rating to a “market perform” rating and set a $25.75 price objective for the company. in a report on Tuesday, May 7th. Svb Leerink lowered shares of Intersect ENT from an “outperform” rating to a “market perform” rating and dropped their price objective for the company from $41.00 to $29.00 in a report on Tuesday, May 7th. Finally, ValuEngine raised shares of Intersect ENT from a “hold” rating to a “buy” rating in a report on Thursday, August 1st. Two analysts have rated the stock with a sell rating, seven have given a hold rating and two have given a buy rating to the company. Intersect ENT currently has an average rating of “Hold” and an average price target of $27.11.

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Legal & General Group Plc lifted its position in Intersect ENT by 14.8% in the fourth quarter. Legal & General Group Plc now owns 5,353 shares of the medical equipment provider’s stock valued at $151,000 after buying an additional 690 shares during the last quarter. Meeder Asset Management Inc. lifted its position in Intersect ENT by 15.0% in the first quarter. Meeder Asset Management Inc. now owns 6,443 shares of the medical equipment provider’s stock valued at $206,000 after buying an additional 839 shares during the last quarter. Quantamental Technologies LLC lifted its position in Intersect ENT by 211.0% in the first quarter. Quantamental Technologies LLC now owns 1,950 shares of the medical equipment provider’s stock valued at $63,000 after buying an additional 1,323 shares during the last quarter. Great Lakes Advisors LLC lifted its position in Intersect ENT by 1.5% in the second quarter. Great Lakes Advisors LLC now owns 99,598 shares of the medical equipment provider’s stock valued at $2,267,000 after buying an additional 1,510 shares during the last quarter. Finally, State Board of Administration of Florida Retirement System lifted its position in Intersect ENT by 14.6% in the first quarter. State Board of Administration of Florida Retirement System now owns 18,275 shares of the medical equipment provider’s stock valued at $588,000 after buying an additional 2,330 shares during the last quarter. 91.62% of the stock is currently owned by institutional investors.

Shares of XENT traded down $0.39 during mid-day trading on Friday, reaching $15.37. The stock had a trading volume of 414,253 shares, compared to its average volume of 462,891. Intersect ENT has a 52-week low of $15.16 and a 52-week high of $35.87. The business’s fifty day moving average is $18.68 and its 200 day moving average is $26.34. The firm has a market cap of $495.70 million, a price-to-earnings ratio of -20.22 and a beta of 0.79.

Intersect ENT Company Profile

Intersect ENT, Inc, a drug delivery company, researches and develops products for the treatment of patients with ear, nose, and throat conditions in the United States. The company offers PROPEL and PROPEL mini drug releasing implants for patients undergoing sinus surgery to treat chronic sinusitis; and PROPEL Contour, a steroid releasing implant to frontal and maxillary sinus ostia, or openings, of the dependent sinuses.

See Also: Day Trading

Get a free copy of the Zacks research report on Intersect ENT (XENT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Intersect ENT (NASDAQ:XENT)

Receive News & Ratings for Intersect ENT Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intersect ENT and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply